Item Type | Name |
Concept
|
Breast Neoplasms
|
Concept
|
Bone Neoplasms
|
Concept
|
Bronchial Neoplasms
|
Concept
|
Colonic Neoplasms
|
Concept
|
Liver Neoplasms
|
Concept
|
Pancreatic Neoplasms
|
Concept
|
Ovarian Neoplasms
|
Concept
|
Lung Neoplasms
|
Concept
|
Prostatic Neoplasms
|
Concept
|
Pleural Neoplasms
|
Concept
|
Thoracic Neoplasms
|
Concept
|
Thymus Neoplasms
|
Concept
|
Neoplasms, Second Primary
|
Concept
|
Cancer Vaccines
|
Concept
|
Stomach Neoplasms
|
Concept
|
Colorectal Neoplasms
|
Concept
|
Breast Neoplasms, Male
|
Concept
|
Brain Neoplasms
|
Concept
|
Neoplasms
|
Concept
|
Neoplasms, Glandular and Epithelial
|
Academic Article
|
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
|
Academic Article
|
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
|
Academic Article
|
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
|
Academic Article
|
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic.
|
Academic Article
|
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
|
Academic Article
|
Severity of COVID-19 in patients with lung cancer: evidence and challenges.
|
Academic Article
|
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.
|
Academic Article
|
The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST.
|
Academic Article
|
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors.
|
Academic Article
|
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
|
Academic Article
|
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME).
|
Academic Article
|
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience.
|
Academic Article
|
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
|
Academic Article
|
Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis.
|
Academic Article
|
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.
|
Academic Article
|
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system.
|
Academic Article
|
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
|
Academic Article
|
Regulation of PD-L1 Expression by NF-?B in Cancer.
|
Academic Article
|
Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
|
Academic Article
|
Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
|
Academic Article
|
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
|
Academic Article
|
Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer.
|
Academic Article
|
Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.
|
Academic Article
|
Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity.
|
Academic Article
|
Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
|
Academic Article
|
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
|
Academic Article
|
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.
|
Academic Article
|
COVID-19 in patients with cancer: managing a pandemic within a pandemic.
|
Academic Article
|
Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study.
|
Academic Article
|
Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
|
Academic Article
|
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
|
Academic Article
|
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
|
Academic Article
|
Immunometabolic Status of COVID-19 Cancer Patients.
|
Academic Article
|
Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
|
Academic Article
|
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial).
|
Academic Article
|
Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem.
|
Academic Article
|
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
|
Academic Article
|
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
|
Academic Article
|
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
|
Academic Article
|
Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
|
Academic Article
|
An oxaliplatin + 5-fluorouracil bolus + folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients.
|
Academic Article
|
Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
|
Academic Article
|
Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.
|
Academic Article
|
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey.
|
Academic Article
|
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
|
Academic Article
|
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
|
Academic Article
|
At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer.
|
Academic Article
|
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
|
Academic Article
|
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
|
Academic Article
|
Localized hand-foot syndrome after intra-arterial hepatic chemotherapy with floxuridine: a clinical case.
|
Academic Article
|
The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate.
|
Academic Article
|
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer.
|
Academic Article
|
A mono-institutional prospective study on the effectiveness of a specialist psychotherapeutic intervention (POI) started at the diagnosis of cancer.
|
Academic Article
|
Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial data.
|
Academic Article
|
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy.
|
Academic Article
|
Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes?
|
Academic Article
|
Perioperative or postoperative therapy for resectable gastric cancer?
|
Academic Article
|
Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
|
Academic Article
|
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis.
|
Academic Article
|
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
|
Academic Article
|
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
|
Academic Article
|
Targeted therapies in small cell lung cancer: a review.
|
Academic Article
|
The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers.
|
Academic Article
|
OncoAlert Round Table Discussions: The Global COVID-19 Experience.
|
Academic Article
|
EGFR mutations and EGFR tyrosine kinase inhibitors.
|
Academic Article
|
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
|
Academic Article
|
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
|
Academic Article
|
Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.
|
Academic Article
|
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.
|
Academic Article
|
Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases.
|
Academic Article
|
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.
|
Academic Article
|
Pembrolizumab plus Chemotherapy in Lung Cancer.
|
Academic Article
|
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
|
Academic Article
|
Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water?
|
Academic Article
|
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.
|
Academic Article
|
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients.
|
Academic Article
|
Response of thymoma to cetuximab.
|
Academic Article
|
To Continue or Not to Continue? That Is the Question.
|
Academic Article
|
Development and clinical indications of cetuximab.
|
Academic Article
|
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration.
|
Academic Article
|
LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial.
|
Academic Article
|
Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
|
Academic Article
|
Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors.
|
Academic Article
|
Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer.
|
Academic Article
|
Predicting response of molecular targeted therapies: a still possible challenge?
|
Academic Article
|
Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment.
|
Academic Article
|
SMO mutations confer poor prognosis in malignant pleural mesothelioma.
|
Academic Article
|
Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.
|
Academic Article
|
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
|
Academic Article
|
RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.
|
Academic Article
|
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
|
Academic Article
|
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
|
Academic Article
|
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.
|
Academic Article
|
Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
|
Academic Article
|
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.
|
Academic Article
|
Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer.
|
Academic Article
|
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
|
Academic Article
|
ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?
|
Academic Article
|
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis.
|
Academic Article
|
BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience.
|
Academic Article
|
Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events.
|
Academic Article
|
Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
|
Academic Article
|
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
|
Academic Article
|
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy.
|
Academic Article
|
Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine.
|
Academic Article
|
?Np63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization.
|
Academic Article
|
Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients.
|
Academic Article
|
Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.
|
Academic Article
|
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
|
Academic Article
|
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
|
Academic Article
|
The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.
|
Academic Article
|
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.
|
Academic Article
|
Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis.
|
Academic Article
|
Cetuximab for colorectal cancer.
|
Academic Article
|
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.
|
Academic Article
|
To target or not to target, that is the question.
|
Academic Article
|
[Locoregional therapy in hepatic metastases of colorectal cancer].
|
Academic Article
|
Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer.
|
Academic Article
|
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
|
Academic Article
|
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
|
Academic Article
|
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.
|
Academic Article
|
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
|
Academic Article
|
First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
|
Academic Article
|
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression.
|
Academic Article
|
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
|
Academic Article
|
Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases.
|
Academic Article
|
Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
|
Academic Article
|
Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
|
Academic Article
|
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
|
Academic Article
|
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
|
Academic Article
|
Maintenance therapy in NSCLC: why? To whom? Which agent?
|
Academic Article
|
Membrane Cholesterol Regulates Macrophage Plasticity in Cancer.
|
Academic Article
|
Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways.
|
Academic Article
|
Predictive models in palliative care.
|
Academic Article
|
Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
|
Academic Article
|
Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections.
|
Academic Article
|
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.
|
Academic Article
|
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
|
Academic Article
|
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.
|
Academic Article
|
Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.
|
Academic Article
|
Across the universe of K-RAS mutations in non-small-cell-lung cancer.
|
Academic Article
|
Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting.
|
Academic Article
|
Cognitive impairment and chemotherapy: a brief overview.
|
Academic Article
|
Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.
|
Academic Article
|
G48A, a New KRAS Mutation Found in Lung Adenocarcinoma.
|
Academic Article
|
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
|
Academic Article
|
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
|
Academic Article
|
Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
|
Academic Article
|
Caring for Patients With Cancer During the COVID-19 Outbreak in Italy.
|
Academic Article
|
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
|
Academic Article
|
Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
|
Academic Article
|
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study.
|
Academic Article
|
Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review.
|
Academic Article
|
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
|
Academic Article
|
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.
|
Academic Article
|
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 =50% who progress on first-line immunotherapy: real-world data from a European cohort.
|
Academic Article
|
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score =50% treated with front-line pembrolizumab.
|
Academic Article
|
A lesson from vorinostat in pleural mesothelioma.
|
Academic Article
|
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.
|
Academic Article
|
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
|
Academic Article
|
Myeloid cell heterogeneity in lung cancer: implication for immunotherapy.
|
Academic Article
|
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
|
Academic Article
|
Targeting the MET gene for the treatment of non-small-cell lung cancer.
|
Academic Article
|
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
|
Academic Article
|
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
|
Academic Article
|
Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers.
|
Academic Article
|
Afatinib for lung cancer: let there be light?
|
Academic Article
|
Thymoma and thymic carcinomas.
|
Academic Article
|
Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.
|
Academic Article
|
Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients.
|
Academic Article
|
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.
|
Academic Article
|
Challenging Lung Carcinoma with Coexistent ?Np63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells.
|
Academic Article
|
Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?
|
Academic Article
|
Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet.
|
Academic Article
|
Recurrent thrombosis followed by Lazarus response in ROS1 rearranged NSCLC treated with crizotinib: a case report.
|
Academic Article
|
New strategies in colon cancer adjuvant therapy.
|
Academic Article
|
LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors.
|
Academic Article
|
Bevacizumab for non-small-cell lung cancer.
|
Academic Article
|
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
|
Academic Article
|
Cetuximab for metastatic colorectal cancer.
|
Academic Article
|
Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?
|
Academic Article
|
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort.
|
Academic Article
|
Diagnosis and management of typical and atypical lung carcinoids.
|
Academic Article
|
New anti-emetic treatments.
|
Academic Article
|
Accuracy of pathologic diagnosis for thymic epithelial tumors: a brief report from an Italian reference Center.
|
Academic Article
|
Treatment of lung large cell neuroendocrine carcinoma.
|
Academic Article
|
Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.
|
Academic Article
|
Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.
|
Academic Article
|
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
|
Academic Article
|
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
|
Academic Article
|
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
|
Academic Article
|
Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
|
Academic Article
|
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer.
|
Academic Article
|
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
|
Academic Article
|
Thymoma and thymic carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations.
|
Academic Article
|
LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments.
|
Academic Article
|
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
|
Academic Article
|
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
|
Academic Article
|
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors.
|
Academic Article
|
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
|
Academic Article
|
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
|
Academic Article
|
Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM).
|
Academic Article
|
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.
|
Academic Article
|
Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations.
|
Academic Article
|
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
|
Academic Article
|
Patient Preferences for Lung Cancer Treatments: A Study Protocol for a Preference Survey Using Discrete Choice Experiment and Swing Weighting.
|
Academic Article
|
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.
|
Academic Article
|
COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response.
|
Academic Article
|
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series.
|
Academic Article
|
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
|
Academic Article
|
Comprehensive metastatic ablation in advanced NSCLC through biology-guided radiotherapy - A path forward?
|
Academic Article
|
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
|
Academic Article
|
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer.
|
Academic Article
|
Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.
|
Academic Article
|
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.
|
Academic Article
|
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy.
|
Academic Article
|
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
|
Academic Article
|
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.
|
Academic Article
|
Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction?
|
Academic Article
|
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
|
Academic Article
|
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis.
|
Academic Article
|
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis.
|
Academic Article
|
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.
|
Academic Article
|
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.
|
Academic Article
|
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy.
|
Academic Article
|
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
|
Academic Article
|
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors.
|
Academic Article
|
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC.
|
Academic Article
|
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.
|
Academic Article
|
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.
|
Academic Article
|
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations.
|
Academic Article
|
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
|
Academic Article
|
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
|
Academic Article
|
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
|
Academic Article
|
Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression.
|
Concept
|
Triple Negative Breast Neoplasms
|
Academic Article
|
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).
|
Academic Article
|
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy.
|
Academic Article
|
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
|
Academic Article
|
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.
|
Academic Article
|
Deep learning generates synthetic cancer histology for explainability and education.
|
Academic Article
|
Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal.
|
Academic Article
|
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
|
Academic Article
|
Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer.
|
Academic Article
|
Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives.
|
Academic Article
|
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
|
Academic Article
|
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
|
Academic Article
|
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
|
Academic Article
|
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
|
Academic Article
|
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.
|
Academic Article
|
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
|
Academic Article
|
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B.
|
Academic Article
|
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
|
Academic Article
|
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
|
Academic Article
|
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).
|
Academic Article
|
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.
|
Academic Article
|
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
|
Academic Article
|
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.
|
Academic Article
|
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
|
Academic Article
|
Mesothelioma: Pleural, Version 1.2024.
|